| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
181.31(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
35,147 |
128,372 |
194,168 |
376,382 |
| Total Sell Value |
$151,895 |
$457,369 |
$591,564 |
$2,613,056 |
| Total People Sold |
2 |
6 |
7 |
9 |
| Total Sell Transactions |
2 |
14 |
19 |
36 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rudnick Seth |
|
– • – |
2020-12-08 |
4 |
AS |
$20.19 |
$265,694 |
I/I |
(13,161) |
44,601 |
|
12% |
|
| Rudnick Seth |
|
– • – |
2020-12-01 |
4 |
AS |
$20.09 |
$10,449 |
I/I |
(520) |
57,762 |
|
31% |
|
| Muir Glenn P |
|
– • – |
2020-11-18 |
4 |
B |
$13.50 |
$675,000 |
D/D |
50,000 |
170,969 |
0.01 |
96% |
|
| Bailey John E. (jack) Jr. |
|
– • – |
2020-11-11 |
4 |
B |
$12.83 |
$51,320 |
D/D |
4,000 |
8,000 |
0.01 |
62% |
|
| Bailey John E. (jack) Jr. |
|
– • – |
2020-11-10 |
4 |
B |
$12.76 |
$51,055 |
D/D |
4,000 |
4,000 |
0.01 |
67% |
|
| Hanson James S. |
General Counsel |
• – – |
2020-09-04 |
4 |
B |
$14.95 |
$14,950 |
D/D |
1,000 |
4,000 |
2.74 |
45% |
|
| Velleca Mark A. |
President and CEO |
• • – |
2020-03-13 |
4 |
OE |
$0.39 |
$1,170 |
D/D |
3,000 |
37,000 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2020-03-13 |
4 |
OE |
$0.39 |
$975 |
D/D |
2,500 |
29,200 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2020-03-13 |
4 |
OE |
$3.72 |
$7,440 |
D/D |
2,000 |
11,000 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2020-01-23 |
4 |
OE |
$0.39 |
$2,340 |
D/D |
6,000 |
34,000 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2020-01-23 |
4 |
OE |
$0.39 |
$1,950 |
D/D |
5,000 |
26,700 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2020-01-23 |
4 |
OE |
$3.72 |
$3,720 |
D/D |
1,000 |
9,000 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2019-07-18 |
4 |
OE |
$3.72 |
$7,440 |
D/D |
2,000 |
8,000 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2019-01-28 |
4 |
OE |
$0.39 |
$2,730 |
D/D |
7,000 |
21,700 |
|
- |
|
| Moses Jennifer K. |
VP of Finance |
• – – |
2019-01-17 |
4 |
OE |
$3.72 |
$7,440 |
D/D |
2,000 |
6,000 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2019-01-17 |
4 |
OE |
$0.39 |
$3,510 |
D/D |
9,000 |
28,000 |
|
- |
|
| Strum Jay |
Chief Scientific Officer |
• – – |
2019-01-02 |
4 |
OE |
$0.30 |
$27,575 |
D/D |
79,818 |
129,237 |
|
- |
|
| Schwalm Cynthia |
|
– • – |
2018-12-26 |
4 |
B |
$18.45 |
$26,196 |
D/D |
1,420 |
1,500 |
0.01 |
- |
|
| Hanson James S. |
General Counsel |
• – – |
2018-12-26 |
4 |
B |
$18.25 |
$18,250 |
D/D |
1,000 |
3,000 |
0.01 |
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-12-17 |
4 |
AS |
$30.00 |
$113,280 |
D/D |
(3,776) |
14,700 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-12-17 |
4 |
OE |
$4.17 |
$15,746 |
D/D |
3,776 |
18,476 |
|
- |
|
| Demaree John |
Chief Commercial Officer |
• – – |
2018-12-10 |
4 |
B |
$33.15 |
$33,151 |
D/D |
1,000 |
5,250 |
0.01 |
- |
|
| Hanson James S. |
General Counsel |
• – – |
2018-12-10 |
4 |
B |
$32.51 |
$32,508 |
D/D |
1,000 |
2,000 |
0.01 |
- |
|
| Moses Jennifer K. |
VP of Finance & Admin |
• – – |
2018-12-07 |
4 |
OE |
$3.72 |
$7,440 |
D/D |
2,000 |
4,000 |
|
- |
|
| Moses Jennifer K. |
VP of Finance & Admin |
• – – |
2018-12-06 |
4 |
AS |
$34.00 |
$25,500 |
D/D |
(750) |
2,000 |
|
- |
|
328 Records found
|
|
Page 8 of 14 |
|
|
0.21 (4.22%) 
